Rinn Pharma & Biopharma joins NordicPharmaTrain network

Rinn Pharma & Biopharma has joined the NordicPharmaTrain network, expanding its European research and training ties from University of Limerick. The partnership is set to support researcher mobility, joint grants and hands-on training in pharmaceutical development.

Why it matters: - The partnership broadens Rinn Pharma & Biopharma’s reach across Nordic and European research ecosystems. - The collaboration is designed to speed pharmaceutical innovation in advanced manufacturing, formulation science, crystallisation and digitalisation. - The move also supports training for visiting researchers and PhD students, which can help build the sector’s talent pipeline.

What happened: - Rinn Pharma & Biopharma announced its inclusion in the NordicPharmaTrain network on Aug. 7, 2026. - The centre is hosted at University of Limerick and includes 11 additional Research Performing Organisations. - NordicPharmaTrain is a European research and training network focused on pharmaceutical innovation. - CMAC (UK) and the Department of Health Technology at DTU Health Tech, Technical University of Denmark, also joined the consortium.

The details: - Rinn Pharma & Biopharma brings academia, industry and wider stakeholders together to address drug development challenges. - The centre focuses on patient-centred medicines for diverse populations and sustainability across pharmaceutical development and manufacturing. - Under the partnership, Rinn Pharma & Biopharma will host visiting researchers and PhD students. - The centre will provide access to laboratories and infrastructure for secondments and hands-on training. - The partners plan joint publications, collaborative grant proposals and long-term research initiatives. - The collaboration promotes researcher mobility and open knowledge-sharing. - Prof. Damien Thompson said the partnership will accelerate Ireland’s role in innovative pharmaceutical solutions and support collaboration on advanced manufacturing, formulation and digital technologies. - Dr. Sarah Hayes said the partnership will expand opportunities for joint research, shared expertise, European funding participation and access to researchers and PhD candidates.

Between the lines: - The deal strengthens Rinn Pharma & Biopharma’s visibility in the Nordic and wider European research community. - The addition of UK and Danish partners suggests the consortium is building a broader cross-border platform rather than a narrow bilateral tie-up. - The focus on sustainability and patient-centred medicines reflects where European pharmaceutical research is heading.

What's next: - Rinn Pharma & Biopharma and its partners will begin organizing researcher exchanges, secondments and training activity. - The consortium is expected to pursue shared funding applications and new research projects. - The partnership should create more opportunities for Irish researchers to work in European networks and for international researchers to access University of Limerick facilities.

The bottom line: - Rinn Pharma & Biopharma is using NordicPharmaTrain to deepen its European footprint and turn collaboration into research output, training and funding opportunities.